Eloxatin®
Oxaliplatin is a platinum-based antineoplastic agent used primarily for the treatment of advanced colorectal cancer. It forms interstrand and intrastrand DNA crosslinks, inhibiting DNA replication and transcription.
| Dosage Form | IV Injectable (Solution for Infusion) |
| Strength | 5 mg/mL; 50 mg, 100 mg, 200 mg vials |
| Storage | Store at 20–25°C. Do not freeze. Protect from light. |
| Category | Oncology |
| Availability | Available for Transfer |
Advanced colorectal cancer (adjuvant treatment of stage III colon cancer after complete resection; treatment of advanced colorectal cancer with 5-FU/leucovorin).
Forms inter- and intra-strand platinum-DNA crosslinks that inhibit DNA replication and transcription, resulting in cell death via apoptosis.
Each Burrard Pharmaceuticals technology transfer package for Oxaliplatin includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.